Psoriasis treatment secukinumab approved by NICE

The monoclonal antibody secukinumab (Cosentyx) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies.

Plaque psoriasis is the most common form of the disease and appears as thick and extensive skin lesions (plaques). | iSTOCK
Plaque psoriasis is the most common form of the disease and appears as thick and extensive skin lesions (plaques). | iSTOCK

Secukinumab is recommended as an option for adults with a Psoriasis Area Severity Index (PASI) score of 10 or more and a Dermatology Life Quality Index (DLQI) score greater than 10.

Further information
NICE technology appraisal TA350

Treatment with secukinumab should be stopped if an adequate response is not achieved by 12 weeks. An adequate response is defined as either a 75% reduction in PASI score, or a 50% reduction in PASI score accompanied by a 5-point reduction in DLQI score.

Clinicians may need to adjust the DLQI score if the patient has any disabilities or communication difficulties that could affect the assessment.

NICE's decision is conditional on the manufacturer providing secukinumab with the discount agreed in the patient access scheme.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases